Your session is about to expire
← Back to Search
Insulin
Subcutaneous Insulin for Diabetic Ketoacidosis (DKA Trial)
N/A
Waitlist Available
Led By Rema A Gupta, MD
Research Sponsored by Rush University Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Eligible Conditions
- Diabetic Ketoacidosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: Subcutaneous InsulinActive Control1 Intervention
Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
Group II: IV Regular InsulinActive Control1 Intervention
Intravenous Regular Insulin 0.1 units/kg/hour
Group III: Intravenous Novolog InsulinActive Control1 Intervention
Intravenous Novolog Insulin 0.1 units/kg/hour
Find a Location
Who is running the clinical trial?
Novo Nordisk A/SIndustry Sponsor
1,549 Previous Clinical Trials
2,443,982 Total Patients Enrolled
Rush University Medical CenterLead Sponsor
435 Previous Clinical Trials
218,590 Total Patients Enrolled
Rema A Gupta, MDPrincipal InvestigatorRush University Medical Center
Share this study with friends
Copy Link
Messenger